Mardi C. Dier has resigned from her position as Chief Financial Officer of ACELYRIN, Inc. through mutual agreement between the Company and Ms. Dier. Her last day of employment with the Company will be August 15, 2023. In connection with Ms. Dier?s resignation, the Company appointed Gil Labrucherie as the Company?s Chief Financial Officer on an interim basis, effective as of August 2, 2023, while the Company conducts a search for a permanent Chief Financial Officer.

In such role, Mr. Labrucherie will serve as the Company?s principal financial officer and principal accounting officer. Prior to consulting, Mr. Labrucherie, age 52, served as Chief Financial Officer of the Company from July 2022 until November 2022 when he stepped down for personal family reasons. From June 2016 until July 2022, Mr. Labrucherie served as Chief Financial Officer for Nektar Therapeutics, and added the role of Chief Operating Officer of Nektar Therapeutics in October 2019.

Mr. Labrucherie received his J.D. from the Berkeley Law School, his B.A. from the University of California, Davis and holds the Certified Financial Analyst designation from the CFA Institute. There are no arrangements or understandings between Mr. Labrucherie and any other person related to Mr. Labrucherie?s appointment as the Company?s interim Chief Financial Officer. There is no family relationship between Mr. Labrucherie and any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company.